BRIACELL THERAPEUTICS CORP.: 10-Q filed 2022-12-14

Name: BRIACELL THERAPEUTICS CORP.: 10-Q filed 2022-12-14
Creator: BRIACELL THERAPEUTICS CORP.

What BRIACELL THERAPEUTICS CORP. reported in its quarterly report filed 2022-12-14 (fiscal Q1 2023): 26 published measures, 52 facts as tagged in accession 0001493152-22-035452.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-12-14
Fiscal period: fiscal Q1 2023
Accession: 0001493152-22-035452 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BRIACELL THERAPEUTICS CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-10-31	38,450,320	USD
At 2022-07-31	42,577,041	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-10-31	10,334,332	USD
At 2022-07-31	10,328,932	USD
At 2021-10-31	1,583,777	USD
At 2021-07-31	27,671,721	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2022-10-31	37,451,976	USD
At 2022-07-31	41,041,652	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	-1,106,541	USD	92
2021-08-01 to 2021-10-31	-27,533,485	USD	92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	-3,542,382	USD	92
2021-08-01 to 2021-10-31	-1,778,599	USD	92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	-47,294	USD	92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-10-31	-61,456,378	USD
At 2022-07-31	-60,349,837	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	15,518,018	shares	92
2021-08-01 to 2021-10-31	15,238,646	shares	92

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	-0.07	USD/shares	92
2021-08-01 to 2021-10-31	-1.81	USD/shares	92

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	1,111,941	USD	92
2021-08-01 to 2021-10-31	518,134	USD	92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	-5,403,151	USD	92
2021-08-01 to 2021-10-31	-2,284,809	USD	92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-10-31	38,223,797	USD
At 2022-07-31	42,346,700	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2021-08-01 to 2021-10-31	979	USD	92

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-10-31	974,050	USD
At 2022-07-31	941,087	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2022-10-31	226,521	USD
At 2022-07-31	230,339	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2022-10-31	29,698	USD
At 2022-07-31	24,103	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	5,403,151	USD	92
2021-08-01 to 2021-10-31	2,284,809	USD	92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	3,255,215	USD	92
2021-08-01 to 2021-10-31	875,636	USD	92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-10-31	15,518,018	shares
At 2022-07-31	15,518,018	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2022-10-31	-138,684	USD
At 2022-07-31	-138,684	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	-1,106,541	USD	92
2021-08-01 to 2021-10-31	-27,533,485	USD	92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	2,147,936	USD	92
2021-08-01 to 2021-10-31	1,409,173	USD	92

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	3,818	USD	92
2021-08-01 to 2021-10-31	3,817	USD	92

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	4,296,610	USD	92
2021-08-01 to 2021-10-31	-25,248,676	USD	92

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	5,595	USD	92
2021-08-01 to 2021-10-31	6,755	USD	92

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2022-08-01 to 2022-10-31	328,468	USD	92
2021-08-01 to 2021-10-31	29,334	USD	92

Inspect the source

Entity: BRIACELL THERAPEUTICS CORP. / CIK 0001610820
Captured: 2026-09-20T09:26:46.138Z
SEC response SHA-256: 9b120e952e46202c087d84b15420884d11dabee9617ee209952acee5219f65e1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001610820.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))